Today’s Rating: What To Expect From Imprimis Pharmaceuticals (NASDAQ:IMMY) After Rodman & Renshaw’s New Coverage?

November 28, 2016 - By Dolores Ford

Today's Rating: What To Expect From Imprimis Pharmaceuticals (NASDAQ:IMMY) After Rodman & Renshaw's New Coverage?

Why Rodman & Renshaw Gives Imprimis Pharmaceuticals (NASDAQ:IMMY) $5 Price Target

Analysts at Rodman & Renshaw initiated coverage on shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) in a a report revealed to clients on Monday morning. The broker set a Buy rating on the $34.32M market cap company.

The stock decreased 0.39% or $0.01 on November 25, hitting $2.54. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 34.42% since April 25, 2016 and is downtrending. It has underperformed by 40.44% the S&P500.

Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on March, 22.

Insitutional Activity: The institutional sentiment increased to 5.5 in 2016 Q2. Its up 4.30, from 1.2 in 2016Q1. The ratio is positive, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.

Moreover, Blackrock Fund has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 32,979 shares. Moreover, Blackrock Inv Mgmt has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 1,966 shares. National Bank Of America Corp De reported 17,797 shares or 0% of all its holdings. Opaleye has invested 0.98% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Northern Tru Corporation accumulated 43,667 shares or 0% of the stock. Pnc Gp holds 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 2,000 shares. The Ontario – Canada-based Manufacturers Life Com The has invested 0% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Vanguard accumulated 168,584 shares or 0% of the stock. Geode Mgmt Limited Liability Com, a Massachusetts-based fund reported 17,570 shares. Marathon Cap Mgmt has invested 0.05% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Granite Inv Ptnrs Ltd Llc accumulated 155,190 shares or 0.05% of the stock. Creative Planning reported 750 shares or 0% of all its holdings. Bard Assocs, a Illinois-based fund reported 65,500 shares. Tower Research Limited Liability Company (Trc) accumulated 548 shares or 0% of the stock. Berson And Corrado Inv Advisors Limited accumulated 31,107 shares or 0.08% of the stock.

Imprimis Pharmaceuticals, Inc. is engaged in the development, production and dispensing of compounded pharmaceuticals. The company has a market cap of $34.32 million. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It currently has negative earnings. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”

IMMY Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.

More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” on August 15, 2016, also Prnewswire.com with their article: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” published on October 17, 2016, Prnewswire.com published: “Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to …” on September 06, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” published on October 20, 2015 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals to Host its Second Quarter 2016 Financial Report …” with publication date: August 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>